Effect of 4 Weeks of Oral Probiotic Desulfovibrio Piger Supplementation on Immunological and Metabolic Parameters in Individuals With Longstanding Type 1 Diabetes
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
20 participants
May 1, 2026
INTERVENTIONAL
Conditions
Summary
The goal is to establish the effect of oral probiotic Desulfovibrio piger (D. piger) supplementation on immunological and metabolic parameters in individuals with longstanding type 1 diabetes with residual beta cell function. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x10 participants to measure effects of D. piger on parameters of systemic and intestinal inflammation and residual beta cell function.
Eligibility
Inclusion Criteria4
- Males or females, age >18 years
- A diagnosis of type 1 diabetes, with duration of more than 5 years, with minimally one of antiGAD65, IA2, ZnT8 autoantibodies present assessed at diagnosis or routine visits at Diabeter Centrum.
- Evidence of remaining residual beta cell function with detectable UCPCR (more than 0.01 nmol/mmol C-peptide/creatinine ratio) and or fasting plasma C-peptide more than 0.2 mmol/L.
- BMI 18-30 kg/m2
Exclusion Criteria13
- Use of antibiotics or proton-pump inhibitors within the last three months before screening or during study period
- Use of other probiotic supplementation within the last month before screening or during study period
- A history of cholecystectomy
- Overt untreated gastrointestinal disease, inflammatory bowel disease or abnormal bowel habits
- Absence of a large bowel (ie colostomy)
- Evidence for comprised immunity (HIV infection, chemotherapy, other autoimmune diseases, systemic anti-inflammatory therapy)
- History of cardiovascular disaeses (CVD) events
- Hepatic enzymes>2.5 higher than the upper limit of normal range, determined during MARVEL visits/routine visits
- Kidney failure (eGFR <15ml.min/1.73m2), dialysis, kidney transplantation,
- Inability or unwillingness to donate feces or urine.
- Smoking or illicit drug use (e.g. MDMA/amphetamine/cocaine/heroin/GHB) in the past three months or use during the study period.
- Alcohol abuse (equal or above 21 units per week)
- Inability or unwillingness to provide informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Probiotic bacteria D. piger (10\^9 colony forming units (CFU) in 10ml PBS containing 10% glycerol and 10% maltodextrin)
Placebo (10ml PBS containing 10% glycerol and 10% maltodextrin)
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07585994